We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cell Block Prep Method Modified for Molecular Studies

By LabMedica International staff writers
Posted on 14 May 2018
Biomarker testing is currently required to guide the selection of a growing number of targeted therapies in patients with a wide range of malignancies. More...
Combined with increasing use of immunostaining for tumor diagnosis, this has substantially increased the demand for the amount of tissue in small specimens.

Recently, next-generation sequencing platforms have entered clinical practice. These platforms afford the ability to consolidate testing of multiple genes and types of alterations into a single platform; however, some next-generation sequencing platforms require substantially larger DNA input than standard molecular methods. For cytology specimens to remain a viable diagnostic modality in the era of personalized medicine, it is crucial for those specimens to consistently provide sufficient material for diagnostic and predictive ancillary studies.

Pathologists from Memorial Sloan Kettering Cancer Center (New York, NY, USA) tested multiple modifications of the cell block preparation protocol to identify a method with the greatest cell capture using split fine-needle aspirations (FNAs) and scrapes from fresh, surgically resected tumors (ex vivo samples). Ex vivo FNAs were prepared using a 25-gauge needle, and scrapes were prepared by gently scraping the cut surface of a tumor with a surgical blade. The team developed an improved HistoGel)-based cell block preparation method. Cellularity yield with the new versus the standard method was assessed in ex vivo split samples and in consecutive clinical fine-needle aspirates processed before and after.

The scientists reported that the key modification in the new method was pretreatment of the pelleted cells with 95% ethanol before the addition of HistoGel (HistoGel + ethanol method). In addition, they optimized the melting conditions of HistoGel and added a dark, inorganic marker to the cell pellets to highlight the desired level of sectioning during microtomy. Cell blocks from ex vivo split samples showed that the HistoGel + ethanol method yielded, on average, an 8.3-fold (range, 1–20) greater cellularity compared with the standard HistoGel-only method. After the switch from the standard HistoGel method to the modified method in their clinical practice, sufficiency of positive fine-needle aspirates for some molecular studies increased from 72% to 97%.

The authors concluded that a modification of the HistoGel-based cell block preparation method that leads to substantial improvement in cell recovery from FNA needle rinses compared with the standard HistoGel method. They showed the validation of this method both in ex vivo split samples and in routine clinical FNAs before and after the implementation of the new method in their laboratory. This protocol is simple and readily adoptable and leads to substantially increased sufficiency of FNA samples for molecular testing. The study was published in the April 2018 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Memorial Sloan Kettering Cancer Center


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.